Extended-Release Naltrexone to Prevent Opioid Relapse in Criminal Justice Offenders | Zendy

Joshua D. Lee | Zendy; Peter D. Friedmann | Zendy; Timothy W. Kinlock | Zendy; Edward V. Nunes | Zendy; Tamara Y. Boney | Zendy; Randall Hoskinson | Zendy; Donna Wilson | Zendy; Ryan McDonald | Zendy; John Rotrosen | Zendy; Marc N. Gourevitch | Zendy; Michael Gordon | Zendy; Marc Fishman | Zendy; Donna T. Chen | Zendy; Richard J. Bonnie | Zendy; James Cornish | Zendy; Sean M. Murphy | Zendy; Charles P. O’Brien | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Extended-Release Naltrexone to Prevent Opioid Relapse in Criminal Justice Offenders

Author(s) -

Joshua D. Lee,

Peter D. Friedmann,

Timothy W. Kinlock,

Edward V. Nunes,

Tamara Y. Boney,

Randall Hoskinson,

Donna Wilson,

Ryan McDonald,

John Rotrosen,

Marc N. Gourevitch,

Michael Gordon,

Marc Fishman,

Donna T. Chen,

Richard J. Bonnie,

James Cornish,

Sean M. Murphy,

Charles P. O’Brien

Publication year - 2016

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1505409

Subject(s) - naltrexone , medicine , opioid , relapse prevention , randomization , opioid use disorder , confidence interval , opioid antagonist , hazard ratio , randomized controlled trial , psychiatry , anesthesia , (+) naloxone , receptor

Extended-release naltrexone, a sustained-release monthly injectable formulation of the full mu-opioid receptor antagonist, is effective for the prevention of relapse to opioid dependence. Data supporting its effectiveness in U.S. criminal justice populations are limited.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research